Increasing Resistance to Vancomycin and Other Glycopeptides in Staphylococcus aureus

Tenover, Fred C.; Biddle, James W.; Lancaster, M. C.

doi:10.3201/eid0702.010237

Cited by 337 publications

(240 citation statements)

References 38 publications

Supporting

Mentioning

228

Contrasting

Unclassified

Order By: Relevance

“…For MRSA, drug resistance is associated with therapeutic failure and increased mortality of human infections (31,32). Glycopeptide (vancomycin) resistance has transferred from enterococci to MRSA (33); the resulting VRSA strains are broadly antibiotic resistant and represent a global infectious threat (34,35). Daptomycin and linezolid have recently been licensed to address the threat of MRSA and VRSA infections (36,37).…”

Section: Selecting For S Aureus Variants With Increased Resistance Tmentioning

confidence: 99%

Small molecule inhibitor of lipoteichoic acid synthesis is an antibiotic for Gram-positive bacteria

Richter

Elli

Kim

et al. 2013

Proc. Natl. Acad. Sci. U.S.A.

127

View full text Add to dashboard Cite

The current epidemic of infections caused by antibiotic-resistant Gram-positive bacteria requires the discovery of new drug targets and the development of new therapeutics. Lipoteichoic acid (LTA), a cell wall polymer of Gram-positive bacteria, consists of 1,3-polyglycerol-phosphate linked to glycolipid. LTA synthase (LtaS) polymerizes polyglycerol-phosphate from phosphatidylglycerol, a reaction that is essential for the growth of Gram-positive bacteria.

show abstract

Section: Selecting For S Aureus Variants With Increased Resistance Tmentioning

confidence: 99%

Small molecule inhibitor of lipoteichoic acid synthesis is an antibiotic for Gram-positive bacteria

Richter

Elli

Kim

et al. 2013

Proc. Natl. Acad. Sci. U.S.A.

127

View full text Add to dashboard Cite

show abstract

“…The MIC 90 of TD-6424 for all strains tested was <2 g/ml. TD-6424 has potential for use against infections with gram-positive anaerobes and deserves further clinical evaluation.The development of resistance in gram-positive organismsincluding Staphylococcus aureus resistant to oxacillin and vancomycin (10,11,13) and linezolid (12) and vancomycinresistant enterococci also resistant to linezolid (4)-has accentuated the need for new antimicrobial agents. Telavancin is a novel glycopeptide that is bactericidal and shows concentration-dependent killing against gram-positive aerobes, including vancomycin-resistant strains (9).…”

mentioning

confidence: 99%

In Vitro Activities of the New Semisynthetic Glycopeptide Telavancin (TD-6424), Vancomycin, Daptomycin, Linezolid, and Four Comparator Agents against Anaerobic Gram-Positive Species and Corynebacterium spp

Goldstein

Citron²,

Merriam³

et al. 2004

Antimicrob Agents Chemother

101

View full text Add to dashboard Cite

Telavancin is a new semisynthetic glycopeptide anti-infective with multiple mechanisms of action, including inhibition of bacterial membrane phospholipid synthesis and inhibition of bacterial cell wall synthesis. We determined the in vitro activities of telavancin, vancomycin, daptomycin, linezolid, quinupristin-dalfopristin, imipenem, piperacillin-tazobactam, and ampicillin against 268 clinical isolates of anaerobic gram-positive organisms and 31 Corynebacterium strains using agar dilution methods according to National Committee for Clinical Laboratory Standards procedures. Plates with daptomycin were supplemented with Ca 2؉ to 50 mg/liter. The MICs at which 90% of isolates tested were inhibited (MIC 90 s) for telavancin and vancomycin were as follows: Actinomyces spp. (n ‫؍‬ 45), 0.25 and 1 g/ml, respectively; Clostridium difficile (n ‫؍‬ 14), 0.25 and 1 g/ml, respectively; Clostridium ramosum (n ‫؍‬ 16), 1 and 4 g/ml, respectively; Clostridium innocuum (n ‫؍‬ 15), 4 and 16 g/ml, respectively; Clostridium clostridioforme (n ‫؍‬ 15), 8 and 1 g/ml, respectively; Eubacterium group (n ‫؍‬ 33), 0.25 and 2 g/ml, respectively; Lactobacillus spp. (n ‫؍‬ 26), 0.5 and 4 g/ml, respectively; Propionibacterium spp. (n ‫؍‬ 34), 0.125 and 0.5 g/ml, respectively; Peptostreptococcus spp. (n ‫؍‬ 52), 0.125 and 0.5 g/ml, respectively; and Corynebacterium spp. (n ‫؍‬ 31), 0.03 and 0.5 g/ml, respectively. The activity of TD-6424 was similar to that of quinupristin-dalfopristin for most strains except C. clostridioforme and Lactobacillus casei, where quinupristin-dalfopristin was three-to fivefold more active. Daptomycin had decreased activity (MIC > 4 g/ml) against 14 strains of Actinomyces spp. and all C. ramosum, Eubacterium lentum, and Lactobacillus plantarum strains. Linezolid showed decreased activity (MIC > 4 g/ml) against C. ramosum, two strains of C. difficile, and 15 strains of Lactobacillus spp. Imipenem and piperacillin-tazobactam were active against >98% of strains. The MICs of ampicillin for eight Clostridium spp. and three strains of L. casei were >1 g/ml. The MIC 90 of TD-6424 for all strains tested was <2 g/ml. TD-6424 has potential for use against infections with gram-positive anaerobes and deserves further clinical evaluation.The development of resistance in gram-positive organismsincluding Staphylococcus aureus resistant to oxacillin and vancomycin (10,11,13) and linezolid (12) and vancomycinresistant enterococci also resistant to linezolid (4)-has accentuated the need for new antimicrobial agents. Telavancin is a novel glycopeptide that is bactericidal and shows concentration-dependent killing against gram-positive aerobes, including vancomycin-resistant strains (9). Unlike vancomycin, TD-6424 has multiple synergistic mechanisms of action resulting in TD-6424's enhanced activity against aerobic gram-positive species (5a, 9). At the MIC, it has exhibited postantibiotic effects of up to 6 h against S. aureus, compared to 2 h for vancomycin (9). TD-6424 is currently in phase 2 trials for serious gram-positive infe...

show abstract

“…The presence of h-VISA may be an important indicator of the insidious decline of the clinical effectiveness of vancomycin in the hospitals (5) but routine screening of S. aureus isolates for vancomycin-heteroresistant subpopulations may not be recommended if clinical data are not available to assess the significance of heteroresistance. Such screening may be undertaken as part of research protocols, but results generated using h-VISA screening methods should not be reported in a patient data record (12).…”

mentioning

confidence: 99%

Susceptibility of Staphylococcus aureus isolates to vancomycin at a university hospital in southern Brazil

Lutz

Barth

2006

Braz. J. Microbiol.

View full text Add to dashboard Cite

show abstract

Increasing Resistance to Vancomycin and Other Glycopeptides in Staphylococcus aureus

Cited by 337 publications

References 38 publications

Small molecule inhibitor of lipoteichoic acid synthesis is an antibiotic for Gram-positive bacteria

Small molecule inhibitor of lipoteichoic acid synthesis is an antibiotic for Gram-positive bacteria

In Vitro Activities of the New Semisynthetic Glycopeptide Telavancin (TD-6424), Vancomycin, Daptomycin, Linezolid, and Four Comparator Agents against Anaerobic Gram-Positive Species and Corynebacterium spp

Susceptibility of Staphylococcus aureus isolates to vancomycin at a university hospital in southern Brazil

Contact Info

Product

Resources

About